InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the t… Read more
InventisBio Co. Ltd. A (688382) - Total Assets
Latest total assets as of June 2025: CN¥1.81 Billion CNY
Based on the latest financial reports, InventisBio Co. Ltd. A (688382) holds total assets worth CN¥1.81 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
InventisBio Co. Ltd. A - Total Assets Trend (2020–2024)
This chart illustrates how InventisBio Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
InventisBio Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
InventisBio Co. Ltd. A's total assets of CN¥1.81 Billion consist of 97.4% current assets and 2.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 82.6% |
| Accounts Receivable | CN¥165.34 Million | 8.6% |
| Inventory | CN¥0.00 | 0.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥591.89K | 0.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how InventisBio Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InventisBio Co. Ltd. A's current assets represent 97.4% of total assets in 2024, an increase from 96.9% in 2020.
- Cash Position: Cash and equivalents constituted 82.6% of total assets in 2024, down from 96.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
InventisBio Co. Ltd. A Competitors by Total Assets
Key competitors of InventisBio Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
InventisBio Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - InventisBio Co. Ltd. A generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - InventisBio Co. Ltd. A is currently not profitable relative to its asset base.
InventisBio Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.17 | 12.74 | 18.03 |
| Quick Ratio | 23.17 | 12.74 | 18.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.68 Billion | CN¥ 1.78 Billion | CN¥ 2.05 Billion |
InventisBio Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between InventisBio Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.34 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | CN¥1.92 Billion |
| Market Capitalization | $1.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values InventisBio Co. Ltd. A's assets below their book value (0.53 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: InventisBio Co. Ltd. A's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for InventisBio Co. Ltd. A (2020–2024)
The table below shows the annual total assets of InventisBio Co. Ltd. A from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.92 Billion | -11.17% |
| 2023-12-31 | CN¥2.16 Billion | -7.90% |
| 2022-12-31 | CN¥2.35 Billion | +193.47% |
| 2021-12-31 | CN¥800.03 Million | -25.36% |
| 2020-12-31 | CN¥1.07 Billion | -- |